Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
71,307.19
(
-2.42%
)
News Focus
News Focus
Post# of 257391
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 29068

Thursday, 11/02/2006 11:14:44 PM

Thursday, November 02, 2006 11:14:44 PM

Post# of 257391
Woof

I’m on record for posting on numerous occasions that Vivitrol, the alcohol-addiction drug from ALKS and CEPH, would be a dog.

Well, it turns out that Vivitrol is a dog. Today, ALKS lowered the Vivitrol sales guidance for the fiscal year ending 3/31/07; the new guidance for cumulative fiscal-year sales is $5-10M.

At this rate, Vivitrol will not even outsell NTMD’s BiDil.

Morale: Trying to treat people who don’t badly want to be treated is a not a great business idea.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today